Identiv Inc (INVE) Stock News

Rosen Law Firm has filed a class action lawsuit against Triller Group Inc. (NASDAQ: ILLR) on behalf of investors who purchased securities between October 16, 2024 and December 29, 2025. The lawsuit alleges that Triller made materially false and misleading statements regarding its control of BKFC, financial reporting compliance, NASDAQ listing requirements, and disclosure controls. Investors who wish to serve as lead plaintiff must file by December 14, 2026.

A shareholder class action lawsuit has been filed against D-Wave Quantum Inc. (NASDAQ: QBTS), alleging that the company made false and misleading statements and overstated its business and financial prospects. Investors who purchased shares between February 26, 2026 and August 25, 2026 and experienced losses are encouraged to contact the law firm. The deadline to be appointed lead plaintiff is December 14, 2026.

Rosen Law Firm has filed securities class action lawsuits against Millrose Properties, Hims & Hers Health, and Doximity for alleged disclosure failures and misleading statements to investors. Millrose Properties is accused of misrepresenting its business objectives and leasing properties at a loss. Investors have until December 8, 2026 to move the court to serve as lead plaintiff.

Rosen Law Firm has filed a securities class action lawsuit against Netcapital Inc. on behalf of investors who purchased securities between December 15, 2021 and September 3, 2026. The lawsuit alleges that Netcapital made false statements and failed to disclose improper revenue recognition from sham consulting agreements, backdated and forged contracts, undisclosed related-party transactions, and false Sarbanes-Oxley certifications. Investors must move the court by December 7, 2026 to serve as lead plaintiff.

Rosen Law Firm is urging investors who purchased Lincoln Educational Services Corporation (LINC) securities between May 11, 2026 and August 9, 2026 to join a class action lawsuit before the November 10, 2026 deadline. The lawsuit alleges that defendants made false statements about the company's admissions process and student conversion rates, claiming the company experienced a significant drop in student starts relative to enrollment, making positive statements about the business materially misleading.

Rosen Law Firm is notifying Beta Bionics, Inc. investors of a November 3, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false statements about its iLet Bionic Pancreas insulin pump, which the FDA found to be malfunctioning and causing dangerously high insulin dosing. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints and hundreds of life-threatening events.

Robbins Geller announces a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' health information with third-party advertising platforms and charging for prescriptions immediately after intake forms despite claiming personalized consultations. The FTC filed a lawsuit on July 29, 2026, leading to a 15% decline in Hims & Hers stock. Investors with substantial losses can seek lead plaintiff status before November 2, 2026.

Rosen Law Firm has filed a class action lawsuit against Duolingo, Inc. on behalf of investors who purchased Class A common stock between May 2, 2025 and February 26, 2026. The lawsuit alleges that Duolingo made materially false statements regarding Daily Active User growth, failed to disclose that increased user friction from ads and subscription upsells was negatively impacting DAU growth, and that low-quality AI-generated content was degrading the product experience and user retention. The lead plaintiff deadline is December 7, 2026.

Rosen Law Firm is notifying investors of Qfin Holdings who purchased securities between March 18, 2026 and August 25, 2026 of an important November 30, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Qfin defendants made false and misleading statements regarding the resiliency of the company's business and downplayed the negative impact of regulatory headwinds on financial results.

Rosen Law Firm is urging AST SpaceMobile investors who purchased securities between March 4, 2025 and July 15, 2026 to join a securities class action lawsuit before the November 13, 2026 lead plaintiff deadline. The lawsuit alleges that AST SpaceMobile made false statements regarding its capital requirements, liquidity position, competitive standing in the satellite D2C market, and user adoption rates in the U.S. and Japan.

Rosen Law Firm has filed securities class action lawsuits against FuelCell Energy, Hyliion Holdings, and Tigo Energy, alleging that defendants made false and misleading statements regarding their business operations and financial prospects. Investors who purchased securities during specified class periods are encouraged to secure counsel before upcoming deadlines, with the FuelCell case having a November 10, 2026 lead plaintiff deadline.

Rosen Law Firm has filed a securities class action lawsuit against The Ensign Group, Inc. on behalf of investors who purchased securities between February 10, 2022 and June 18, 2026. The lawsuit alleges that Ensign made false and misleading statements regarding its business practices, including systematic neglect of elderly residents, fraudulent Medicaid/Medicare billing, falsification of nursing assistant hours, and illegal licensing schemes. Investors who wish to serve as lead plaintiff must file by December 7, 2026.

Rosen Law Firm announces a securities class action lawsuit against DICK'S Sporting Goods, alleging the company made materially false and misleading statements regarding its Foot Locker acquisition cleanup efforts and exposure to excess inventory and promotional pressures in the athletic footwear industry. Investors who purchased DKS stock between September 8, 2025 and August 24, 2026 may be eligible for compensation. The lead plaintiff deadline is November 3, 2026.

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Coastal Financial Corporation on behalf of investors who purchased securities between October 28, 2024 and July 29, 2026. The lawsuit alleges that Coastal failed to disclose material deterioration in a $500 million CCBX partner loan portfolio and inadequate risk management practices. On July 30, 2026, Coastal announced a $42.1 million net loss driven by a $68.8 million credit expense, causing the stock to plunge 43.5% from $70.66 to $39.91 per share.

A securities fraud class action lawsuit has been filed against Alphabet Inc. on behalf of investors who purchased securities between May 19, 2026 and July 16, 2026. The lawsuit alleges that Alphabet failed to disclose that its Gemini 3.5 Pro AI model was delivering disappointing training results and would face significant launch delays. Following Bloomberg's July 16 report confirming the delays, Alphabet shares declined 4.4%. Google subsequently announced it would release Gemini 4 Argon instead and no longer plans to release Gemini 3.5 Pro.

Rosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages.

Girard Sharp LLP is investigating potential securities claims on behalf of former Lennar Corporation investors who received Millrose Properties, Inc. shares in a February 2025 spin-off. Millrose's stock price has declined significantly since the spin-off completion, prompting the law firm to seek affected investors for a class action lawsuit.

Rosen Law Firm has filed securities class action lawsuits against multiple companies. The primary case involves Hims & Hers Health, Inc., alleging the company made false statements about data privacy, charged consumers for prescriptions without proper consultation, and failed to disclose regulatory scrutiny. The firm is seeking lead plaintiffs with a November 2, 2026 deadline. Similar lawsuits have been filed against Papa John's International and Millrose Properties.

Rosen Law Firm announces securities class action lawsuits against Papa John's International (PZZA) and other companies. The Papa John's lawsuit alleges the company made materially false statements about its transformation efforts, concealing that the process was taking longer than expected and failing to prevent market share losses. Investors who purchased stock during the class period may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.

Pomerantz LLP is investigating potential securities fraud claims on behalf of lululemon investors following the company's September 3, 2026 earnings report, which revealed lower-than-expected revenue, sharply reduced full-year guidance, and negative media commentary. The announcement triggered a 17.38% stock price decline ($21.16 per share) on September 4, 2026.

Pomerantz LLP is investigating potential securities fraud claims against ServiceTitan, Inc. following the company's September 8, 2026 earnings report. ServiceTitan disclosed that its AI software 'Max' requires substantial change management and will not be billed in the first quarter of upsell contracts, resulting in slower revenue growth and reduced professional services revenue by approximately $2 million for the remainder of fiscal 2027. The stock price fell 29.98% to $57.12 per share on September 9, 2026.

Pomerantz LLP is investigating potential securities fraud claims against Corning Incorporated following the company's announcement of a $2 billion at-the-market equity offering on September 11, 2026. Corning's stock price declined $22.80 per share (13.7%) to $143.60 on September 14, 2026, following the announcement.

Pomerantz LLP is investigating potential securities fraud claims against J.B. Hunt Transport Services following the company's September 16, 2026 warning of a 5-10% sequential earnings decline in Q3 2026. The decline was attributed to rising diesel fuel prices and a $25 million unexpected surge in driver expenses. The announcement triggered a 13.3% stock price drop, falling $36.52 to $236.73 per share.

Pomerantz LLP is investigating potential securities fraud claims against Pasqal Holding SA after the company announced on September 28, 2026, that it was ending its participation in France's LSQUARE/PROQCIMA quantum-computing program. The announcement triggered an 8.36% stock price decline, falling $0.56 per share to $6.14.

Pomerantz LLP is investigating potential securities fraud claims on behalf of HCA Healthcare investors following the company's July 14, 2026 announcement of sharply lowered full-year profit guidance due to an unfavorable shift in payer mix that impacted revenue by approximately $400 million in Q2. The news triggered a 6.95% stock price decline.

Pomerantz LLP is investigating potential securities fraud claims against ClearPoint Neuro following a significant stock price decline. On September 29, 2026, development partner uniQure announced that their joint treatment for Huntington's disease failed to achieve statistical significance on a primary clinical measure at 48 months, causing ClearPoint's stock to plummet 23.12% to $11.77 per share.

Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 study results for dabogratinib. Despite claims of a favorable safety profile, the trial showed Grade 3 adverse events in 9-14% of participants, leading to a 17.66% stock price decline on September 9, 2026.

Pomerantz Law Firm has filed a class action lawsuit against Coastal Financial Corporation (CCB) for alleged securities fraud. The lawsuit stems from Coastal's July 30, 2026 earnings announcement, which revealed a surprise $42.1 million GAAP net loss driven by a $68.8 million credit expense related to a CCBX partner relationship involving approximately $500 million in underlying loans. The disclosure triggered a 43.5% stock price decline. Investors have until December 1, 2026 to request Lead Plaintiff status.

Pomerantz LLP is investigating Medline Inc. for potential securities fraud following an FDA warning letter in June 2026 detailing significant manufacturing violations. The company's stock fell 7.16% on the FDA announcement and an additional 12.79% in August when Medline disclosed that remediation efforts resulted in earnings losses.

Pomerantz Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud related to its iLet insulin pump device. The company allegedly misrepresented FDA concerns and failed to properly report thousands of patient complaints. The lawsuit follows significant stock price declines after the FDA issued a warning letter in February 2026, revealing more serious safety and reporting issues than Beta Bionics had previously disclosed. Investors have until November 3, 2026, to join the class action.